At Kye, our marketed products are the keys to therapeutic relief for patients today. Our pipeline fuels hope for the future.
With a number of lead products in cardiology, pediatrics and neurosciences, Kye is poised to become a major contributor to improving the health of Canadians in a meaningful way.
We are proud of the medicines we have licensed already and the positive impact they are providing for a growing number of people – and we are just getting started. Kye is continuously sourcing new opportunities to address clinically significant unmet needs.
CORZYNA™ (ranolazine extended-release tablets) is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers.
EN
FR
Product Monograph
Healthcare Provider Fact Sheet
Patient Safety Information Leaflet
CORZYNA™ Purchase Support Program Information (All Provinces Except Quebec)
CORZYNA™ Patient d’Exception Bridging Program Overview (Quebec)
CORZYNA™ Patient d’Exception Bridging Program Enrolment Form (Quebec)
CORZYNA™ Patient Support Program Enrollment Form
Read More
KYE-ESCITALOPRAM
KYE-ESCITALOPRAM
(escitalopram oxalate 15 mg tablets)
KYE-ESCITALOPRAM (escitalopram 15 mg tablets) is indicated for the symptomatic relief of Major Depressive Disorder (MDD).
EN
FR
Product Monograph
Healthcare Provider Fact Sheet
Patient Safety Information Leaflet
KYE-ESCITALOPRAM Purchase Support Program Information (All Provinces Except Quebec)
KYE-ESCITALOPRAM Patient d’Exception Bridging Program Overview (Quebec)
KYE-ESCITALOPRAM Patient d’Exception Bridging Program Enrolment Form (Quebec)
KYE-ESCITALOPRAM Patient Support Program Enrollment Form
Read More
FIRDAPSE ®
FIRDAPSE ®
(amifampridine phosphate)
FIRDAPSE® (amifampridine) is indicated for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults. FIRDAPSE® should only be prescribed by health professionals who have experience in the treatment of LEMS, are knowledgeable of the efficacy and safety profile of this drug, and are able to discuss benefits/risks of treatment with patients.
EN
FR
Product Monograph
Healthcare Provider Fact Sheet
Patient Safety Information Leaflet
FIRDAPSE ® Purchase Support Program Information (All Provinces Except Quebec)
FIRDAPSE ® Patient d’Exception Bridging Program Overview (Quebec)
FIRDAPSE ® Patient d’Exception Bridging Program Enrolment Form (Quebec)
FIRDAPSE ® Patient Support Program Enrollment Form
QUILLIVANT® ER Chewable Tablets (methylphenidate hydrochloride extended-release chewable tablets) are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children (6-12 years of age).
EN
FR
Product Monograph
Healthcare Provider Fact Sheet
Patient Safety Information Leaflet
QUILLIVANT® ER Chewable Tablets Purchase Support Program Information (All Provinces Except Quebec)
QUILLIVANT® ER Chewable Tablets Patient d’Exception Bridging Program Overview (Quebec)
QUILLIVANT® ER Chewable Tablets Patient d’Exception Bridging Program Enrolment Form (Quebec)
QUILLIVANT® ER Chewable Tablets Patient Support Program Enrollment Form
Read More
QUILLIVANT® ER Oral Suspension
QUILLIVANT® ER Oral Suspension
methylphenidate hydrochloride extended-release powder for oral suspension
QUILLIVANT® ER Oral Suspension (methylphenidate hydrochloride extended-release powder for oral suspension) are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children (6-12 years of age).
EN
FR
Product Monograph
Healthcare Provider Fact Sheet
Patient Safety Information Leaflet
QUILLIVANT® ER Oral Suspension Purchase Support Program Information (All Provinces Except Quebec)
QUILLIVANT® ER Oral Suspension Patient d’Exception Bridging Program Overview (Quebec)
QUILLIVANT® ER Oral Suspension Patient d’Exception Bridging Program Enrolment Form (Quebec)
QUILLIVANT® ER Oral Suspension Patient Support Program Enrollment Form
Read More
ACCRUFeR®
ACCRUFeR®
Capsules, 30 mg iron (as ferric maltol)
ACCRUFeR (ferric maltol capsules) is indicated for the treatment of iron deficiency anemia in adult patients who are unresponsive or intolerant to other oral iron preparations.
EN
FR
Product Monograph
Healthcare Provider Fact Sheet
Patient Safety Information Leaflet
ACCRUFeR® Purchase Support Program Information (All Provinces Except Quebec)
ACCRUFeR® Patient d’Exception Bridging Program Overview (Quebec)
ACCRUFeR® Patient d’Exception Bridging Program Enrolment Form (Quebec)
ACCRUFeR® Patient Support Program Enrollment Form
Read More
It is our mission to evaluate all opportunities that will improve the lives of Canadians.
If you currently are a patient or a health care professional experiencing sub-optimal care or lack of options in practice due to a specific medicine not being available in Canada, please contact us.
